First Study to Investigate Therapeutic Advantages of Managing Lung Cancer Through Telemedicine

Web Exclusives —April 2, 2021


Lung Cancer

For patients with lung cancer, quality of life (QOL) is negatively impacted by the deterioration of physical and psychological function. For patients with chronic diseases, there has been a demonstrated record of using telemedicine as an effective intervention to assist with clinical management concerns. Telemedicine has been recommended as an intervention that is safe, time-efficient, and cost-effective, and has emerged over the past 2 decades as a noninvasive monitoring system that could be implemented as part of routine follow-up for discharged patients.

A systematic review and meta-analysis was conducted to investigate the usefulness of employing telemedicine in the treatment of patients with lung cancer, as measured by improvement in QOL. Investigators searched a wide range of databases for randomized controlled trials that investigated the effectiveness of telemedicine in patients with lung cancer.

Eight clinical trials with a total of 635 patients with lung cancer were included in the meta-analysis. The data showed that the telemedicine group had a significantly higher QOL than the usual-care group, with lower levels of anxiety and less depression. However, fatigue and pain outcomes between the 2 groups were not significantly different.

The management of lung cancer was greatly improved with telemedicine; remarkably, investigators demonstrated through subgroup analysis that the telemedicine cohort was significantly improved when telephone-based intervention was utilized. Furthermore, during long-term follow-up, the telemedicine group had a substantially improved QOL compared with the usual-care group.

The unique ability of telemedicine to overcome distance barriers between patients and clinics helps to explain the improved QOL experienced by patients. Long-term management of patients may also benefit from telemedicine, but this requires further study and follow-up to determine its advantages over usual care. Study results suggested that telephone-based interventions may be more helpful than website-based technology; this may be due to the fact that patients with lung cancer tend to be older and are more comfortable using telephones to communicate.

This may be the first meta-analysis of the value of telehealth care in patients with lung cancer; however, interventions in the telemedicine arm in this study included not only telephone and Internet but also noninvasive interventions, such as exercise programs and depression care. While these studies were highly heterogeneous, in terms of the significant amount of variation in technology medium, follow-up time, and type of provider with whom patients were in contact, the investigators concluded that an effective means of improving QOL in patients with lung cancer is to integrate telemedicine into clinical practice. They suggest that additional resources should be channeled into telemedicine care development and more high-quality, randomized controlled trials be conducted to investigate the importance of telemedicine in the management of lung cancer, based on patient outcomes.


Pang L, Liu Z, Lin S, et al. The effects of telemedicine on the quality of life of patients with lung cancer: a systematic review and meta-analysis. Ther Adv Chronic Dis. 2020;11:2040622320961597.

Related Articles
American Cancer Society Cancer Action Network Releases Recommendations to Increase Cancer Biomarker Testing
Web Exclusives
The American Cancer Society Cancer Action Network has published data that demonstrate there are multiple barriers to biomarker testing access and released recommendations that address these barriers.
Sotorasib Demonstrates Efficacy in CodeBreaK 100 Phase 2 Study Results
Web Exclusives
Sotorasib has shown promising antitumor activity in phase 2 of a clinical trial of patients with heavily treated advanced NSCLC.
Results of an International Study Identify Barriers to Molecular Testing in NSCLC
Web Exclusives
Recently released survey responses identified multiple barriers to, and dissatisfaction with, the current state of molecular testing in lung cancer.
Last modified: April 2, 2021

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
    Profession or Role
    Primary Specialty or Disease State
  • Please enter your mailing address.

    Address Line 2
    Zip Code